Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 14 August, 2001

Xenova Group PLC

Re Agreement

Xenova Group PLC
14 August 2001

                                                         FOR IMMEDIATE RELEASE

                             Xenova Group plc

    US$105m (£75m) North American collaboration with QLT Inc for multi-drug
                         resistance modulator XR9576

Slough, UK, 14th August 2001 - Xenova Group plc (Nasdaq NM: XNVA; London Stock
Exchange: XEN) today announces that it has signed an exclusive licence
agreement with Vancouver-based QLT Inc (Nasdaq NM: QLTI; TSE: QLT) for the
development and for the marketing in the United States, Canada and Mexico of
Xenova's multi-drug resistance (MDR) modulator, XR9576, for the treatment of
MDR in cancer.

In selecting the most suitable development and commercialisation partner for
XR9576 and in line with its goal of maximising the product's potential in the
market, Xenova's objective was to find a partner that has a commitment with
respect to oncology, possesses strong clinical development expertise, the
financial resources to fully support the programme and, most importantly, does
not have a vested interest in a particular chemotherapeutic agent which might
present it with a conflict in terms of maximally exploiting XR9576's

QLT is a world leader in photodynamic therapy (PDT) using light-activated
drugs to treat eye disease and various cancers. Based in Vancouver, Canada,
and founded in 1981, QLT discovered and developed Photofrin(R), the world's
first PDT drug used in cancer, and Visudyne(TM), a PDT drug for the treatment of
wet, age related macular degeneration which is partnered with Novartis AG and
approved in almost 50 countries around the world.  QLT has stated its
objective is to build an integrated biopharmaceutical company and will use
this opportunity to establish an oncology franchise.

Under the terms of the agreement, QLT will assume responsibility for the
further development of XR9576, including Phase III trials, all regulatory
filings and the manufacture and sale of XR9576 within those territories
covered by the agreement.  QLT will make an immediate upfront licence payment
of US$10m (£7.1m) to Xenova and will provide up to $45m (£32.0m) in funding
for all development activities related to Phase III clinical studies for
XR9576 in North America and Europe.  Milestones of up to US$50m (£35.6m) and
royalties in the range of 15 to 22 per cent depending on the level of North
American sales are also receivable by Xenova.

Xenova retains all rights to XR9576 outside the United States, Canada and
Mexico, including European and Rest of World marketing rights.

Xenova has obtained US FDA agreement to proceed with Phase III development for
XR9576.  QLT will adopt and refine the clinical plan and the Phase III
programme is expected to begin in the first half of 2002 once the clinical
study protocol is finalised. It is anticipated that QLT will file for
marketing approval of XR9576 in first line treatment in combination with
chemotherapy in advanced non-small cell lung cancer (NSCLC) in 2005.

NSCLC is the first of several indications in which XR9576 will be
investigated. Other potential cancer indications include breast, ovarian,
acute myeloid leukaemia, sarcoma and colorectal.

David Oxlade, Chief Executive of Xenova, commented:

'This deal with QLT allows us to proceed as planned with pivotal studies in
Europe and the US, and gives us a strong development partner with a commitment
to establishing a dedicated oncology marketing and infrastructure in the US.

'Importantly, this deal retains for Xenova all rights to XR9576 in Europe and
the Rest of the World and, as we move towards obtaining marketing approvals,
we shall be establishing further commercial partnerships to maximise the value
of this important new therapeutic approach.'

Julia Levy, President and CEO of QLT, said:

'This collaboration underlines QLT's commitment to oncology and to expand
beyond photodynamic therapy and supports our longer term plan to become a
fully integrated biopharmaceutical company with a North American sales force.

'Our internal evaluation of this product confirms that XR9576 is the leading
MDR inhibitor in development based on its potency, selectivity and stage of
development. We have proven our drug development capabilities with the
commercialisation of Visudyne(TM) and Photofrin(R) and look forward to applying
our expertise to the development of XR9576 in an area with such a high unmet
clinical need.'



Xenova Group plc                                      Financial Dynamics

David Oxlade, Chief Executive Officer                 David Yates/Fiona Noblet
Daniel Abrams, Finance Director                       Tel: +44(0) 207 831 3113
Hilary Reid Evans, Head of Corporate Communications
Tel: +44 (0) 1753 706600


Elayne Wandler or Tamara Hicks
Tel: (001) 604 872 7881 Fax: (001) 604 873 0816

A presentation for analysts will be held at 9am at the offices of Nomura
International plc, Nomura House, 1 St. Martin's le Grand, London EC1A 4NP.
Please contact Mo Noonan on 0207 269 7116 for further details.

Notes to Editors

Xenova Group plc's product pipeline focuses principally on the therapeutic
areas of cancer, infectious, autoimmune and cardiovascular diseases.  The
Group has a well-established track record in the identification, development
and partnering of innovative products and technologies.  The Group has
partnerships with a number of major pharmaceutical companies including Glaxo
SmithKline, Lilly, Pfizer and Celltech.


One of the major barriers to successful cancer chemotherapy is the development
by cancer cells of resistance to those drugs being used for treatment.  XR9576
targets this drug resistance mechanism through the inhibition of
P-glycoprotein, a membrane based 'pump' that acts to expel the cytotoxic drug
from the tumour cell, preventing the cytotoxic drug from being fully
effective.  XR9576 has completed a series of three separate Phase IIa trials,
in which XR9576 was administered together with three of the world's
best-selling cytotoxic drugs, each of which is known to be affected by the
resistance mechanism.  The successful outcome of these trials was announced in
late 2000/early 2001.  The trials demonstrated that the combination of XR9576
with the cytotoxic drug was safe and well tolerated and the no clinically
significant pharmacokinetic interaction occurred between XR9576 and the
cytotoxic drug.  This allows the cytotoxic drug to be administered at or close
to its full normal clinical dose, which is of potentially significant
therapeutic benefit.  A number of complete and partial responses (elimination
or shrinkage of the tumour) were observed to occur during these open label and
uncontrolled studies.

For further information about Xenova and its products please visit the Xenova
website at

QLT Inc is a world leader in photodynamic therapy, a field of medicine
utilising light-activated drugs in the treatment of disease.  QLT's innovative
science has led to the development and commercialisation of breakthrough
treatments utilising this technology for applications in ophthalmology and
oncology and is exploring the potential in other diseases.  For more
information you are invited to visit QLT's website at

Visudyne(TM) is a trademark of Novartis AG

PHOTOFRIN(R) is a registered trademark of Axcan Pharma

Safe Harbor Statement under the US Private Securities Litigation Reform Act of
1995: Some or all of the statements in this document that relate to future
plans, expectations, events, performances and the like are forward-looking
statements, as defined in the US Private Securities Litigation Reform Act of
1995.  Actual results of events could differ materially from those described
in the forward-looking statements due to a variety of factors, including those
set forth in the Company's filings with the US Securities and Exchange


a d v e r t i s e m e n t